Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.

Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC.

J Hematol Oncol. 2014 Aug 1;7:52. doi: 10.1186/s13045-014-0052-x.

2.

Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.

Feldman DR, Patil S, Trinos MJ, Carousso M, Ginsberg MS, Sheinfeld J, Bajorin DF, Bosl GJ, Motzer RJ.

Cancer. 2012 Feb 15;118(4):981-6. doi: 10.1002/cncr.26375. Epub 2011 Jul 26.

3.

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.

Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C, Kollmannsberger C.

Ann Oncol. 2011 Dec;22(12):2654-60. doi: 10.1093/annonc/mdr026. Epub 2011 Mar 17.

PMID:
21415240
4.

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors.

Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ, Motzer RJ.

Invest New Drugs. 2010 Aug;28(4):523-8. doi: 10.1007/s10637-009-9280-2. Epub 2009 Jun 23.

PMID:
19547919
5.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

6.

Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A.

Cancer Med. 2016 Jul;5(7):1416-24. doi: 10.1002/cam4.713. Epub 2016 Apr 25.

7.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L.

Ann Oncol. 2015 Oct;26(10):2125-32. doi: 10.1093/annonc/mdv310. Epub 2015 Jul 21. Erratum in: Ann Oncol. 2015 Dec;26(12):2507-8.

8.

Sunitinib: from rational design to clinical efficacy.

Chow LQ, Eckhardt SG.

J Clin Oncol. 2007 Mar 1;25(7):884-96. Review.

PMID:
17327610
9.

Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.

Maroto P, Huddart R, Garcia del Muro X, Horwich A, Paz Ares L, Aparicio J, Germa-Lluch JR.

Oncology. 2011;80(3-4):219-22. doi: 10.1159/000329041. Epub 2011 Jul 4.

PMID:
21734411
10.

Investigational targeted therapies for the treatment of testicular germ cell tumors.

Oing C, Kollmannsberger C, Oechsle K, Bokemeyer C.

Expert Opin Investig Drugs. 2016 Sep;25(9):1033-43. doi: 10.1080/13543784.2016.1195808. Epub 2016 Jun 10. Review.

PMID:
27286362
11.

Activity of sunitinib in extraskeletal myxoid chondrosarcoma.

Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, Gronchi A, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestro R, Pilotti S, Casali PG.

Eur J Cancer. 2014 Jun;50(9):1657-64. doi: 10.1016/j.ejca.2014.03.013. Epub 2014 Apr 2.

PMID:
24703573
13.

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect.

Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG, Pilotti S.

Ann Oncol. 2011 Jul;22(7):1682-90. doi: 10.1093/annonc/mdq644. Epub 2011 Jan 17.

PMID:
21242589
14.

Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.

Papaetis GS, Syrigos KN.

BioDrugs. 2009;23(6):377-89. doi: 10.2165/11318860-000000000-00000. Review.

PMID:
19894779
15.

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.

Ströbel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A.

Br J Cancer. 2010 Jul 13;103(2):196-200. doi: 10.1038/sj.bjc.6605740. Epub 2010 Jun 22.

16.

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H.

Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.

17.

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.

JAMA. 2006 Jun 7;295(21):2516-24.

PMID:
16757724
18.

Phase II study of everolimus in refractory testicular germ cell tumors.

Mego M, Svetlovska D, Miskovska V, Obertova J, Palacka P, Rajec J, Sycova-Mila Z, Chovanec M, Rejlekova K, Zuzák P, Ondrus D, Spanik S, Reckova M, Mardiak J.

Urol Oncol. 2016 Mar;34(3):122.e17-22. doi: 10.1016/j.urolonc.2015.10.010. Epub 2015 Nov 21.

PMID:
26612480
19.

Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.

Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A.

Am J Clin Oncol. 2006 Feb;29(1):12-3.

PMID:
16462496
20.

Supplemental Content

Support Center